140 related articles for article (PubMed ID: 820673)
21. Experimental and clinical trials with BCG immunotherapy.
Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL
Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024
[No Abstract] [Full Text] [Related]
22. Proceedings: Recent studies with the methanol extraction residue fraction of tubercle bacilli (MER): efficacy of distal administration against solid tumors of experimental animals, and stimulation of cellular immunologic responsiveness in cancer patients.
Weiss DW; Cohen D; Yron I; Stupp Y; Izak G
Isr J Med Sci; 1975 Dec; 11(12):1397. PubMed ID: 1218995
[No Abstract] [Full Text] [Related]
23. Studies on the immunogical effects of BCG and its components: theoritical and therapeutic implications.
Mitchell MS
Biomedicine; 1976; 24(4):209-13. PubMed ID: 791387
[TBL] [Abstract][Full Text] [Related]
24. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
25. Modified multiplex PCR for identification of Bacillus Calmette-Guérin substrain Tokyo among clinical isolates.
Seki M; Sato A; Honda I; Yamazaki T; Yano I; Koyama A; Toida I
Vaccine; 2005 May; 23(24):3099-102. PubMed ID: 15837207
[TBL] [Abstract][Full Text] [Related]
26. Nonspecific stimulation and modulation of the immune response and of states of resistance by the methanol-extraction residue fraction of tubercle bacilli.
Weiss DW
Natl Cancer Inst Monogr; 1972 Dec; 35():157-71. PubMed ID: 4633406
[No Abstract] [Full Text] [Related]
27. Activated macrophages and the antitumor action of BCG.
Alexander P
Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313
[No Abstract] [Full Text] [Related]
28. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
Dubois JB; Serrou B
Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
[TBL] [Abstract][Full Text] [Related]
29. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
[TBL] [Abstract][Full Text] [Related]
30. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
[TBL] [Abstract][Full Text] [Related]
31. [Immunochemistry of tubercle bacilli, with special reference to adjuvant activity (author's transl)].
Azuma I
Kekkaku; 1981 Dec; 56(12):595-607. PubMed ID: 7035731
[No Abstract] [Full Text] [Related]
32. Mycobacterial antibodies after tuberculin testing, BCG- vaccination, BCG-immunotherapy and against cross-reacting antigens in a solid-phase radioimmunoassay.
Mauch H; Brehmer W
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Mar; 251(3):380-8. PubMed ID: 6805156
[TBL] [Abstract][Full Text] [Related]
33. The immune response in acute myelocytic leukemia: effect of the methanol extraction residue fraction of tubercle bacilli (MER) on T and B cell functions and their relation to the course of the disease.
Izak G; Stupp Y; Manny N; Zajicek G; Weiss DW
Isr J Med Sci; 1977 Jul; 13(7):677-93. PubMed ID: 411767
[No Abstract] [Full Text] [Related]
34. Correlations between humoral immunity and successful chemotherapy-immunotherapy.
Cantrell JL; Killion JJ; Kollmorgen GM
Cancer Res; 1976 Sep; 36(9 pt.1):3051-7. PubMed ID: 788896
[TBL] [Abstract][Full Text] [Related]
35. Enzyme-linked immunosorbent assay (ELISA) with mycobacterial crude antigens for the sero-epidemiological diagnosis of active tuberculosis.
Escobar-Gutierrez A; Amezcua-Chavarria ME; Pasten-Sanchez S; Ramirez-Casanova E; Cazares JV; Granados G; Loo-Mendez E; Cicero R
Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):417-27. PubMed ID: 9030108
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-Guérin.
Richman SP; Gutterman JU; Hersh EM; Burgess MA; Mavligit GM
Cancer Treat Rep; 1977; 61(3):471-2. PubMed ID: 872144
[No Abstract] [Full Text] [Related]
37. Modulation of the immune response by a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Relationship of antigen dose to heightened primary and secondary immune responses to sheep red blood cells.
Yashphe DJ
Clin Exp Immunol; 1972 Dec; 12(4):497-506. PubMed ID: 4568152
[TBL] [Abstract][Full Text] [Related]
38. Preclinical study of iv administration of the methanol extraction residue of bacillus Calmette-Guérin.
Vogl SE; Lumb G; Bekesi JG; Holland JF
Cancer Treat Rep; 1977 Aug; 61(5):901-3. PubMed ID: 329984
[No Abstract] [Full Text] [Related]
39. Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts.
Weiss DW; Bonhag RS; Leslie P
J Exp Med; 1966 Dec; 124(6):1039-65. PubMed ID: 4288701
[TBL] [Abstract][Full Text] [Related]
40. Comparison between the effects of Micrococcus, BCG and related polysaccharides in preclinical chemo-immunotherapy of murine L 1210 leukaemia [proceedings].
Verloes R; Atassi G; Dumont P; Kanarek L
Arch Int Physiol Biochim; 1978 Oct; 86(4):969-71. PubMed ID: 84653
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
